
ASLAN Pharmaceuticals Limited ASLN
Geschäftsbericht 2020
hinzugefügt 19.08.2023
ASLAN Pharmaceuticals Limited Langfristiger Schuldenstrom 2011-2026 | ASLN
Langfristiger Schuldenstrom Jährlich ASLAN Pharmaceuticals Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 272 K | 265 K | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 272 K | 265 K | 268 K |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Aligos Therapeutics
ALGS
|
3.58 M | $ 8.57 | -0.81 % | $ 84.7 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.73 | 1.78 % | $ 8.97 B | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 99.22 | 2.61 % | $ 27.2 B | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Cabaletta Bio
CABA
|
3.46 M | $ 3.26 | 1.87 % | $ 328 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 21.41 | 0.21 % | $ 1 B | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Clearside Biomedical
CLSD
|
364 K | - | - | $ 25.3 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
3.55 M | $ 1.53 | 4.08 % | $ 393 M | ||
|
Evogene Ltd.
EVGN
|
716 K | $ 0.82 | 0.51 % | $ 27.9 M | ||
|
Forte Biosciences
FBRX
|
416 K | $ 32.45 | 6.03 % | $ 420 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.03 | 3.7 % | $ 4.99 M | ||
|
Aquestive Therapeutics
AQST
|
631 K | $ 4.15 | -0.95 % | $ 444 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 25.2 | 4.48 % | $ 3.21 B | ||
|
Chimerix
CMRX
|
642 K | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
1.16 M | - | - | $ 401 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
1.55 M | $ 33.28 | 2.12 % | $ 2.21 B | ||
|
Galectin Therapeutics
GALT
|
22 K | $ 2.45 | 4.26 % | $ 157 M | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.5 | 2.04 % | $ 399 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Cidara Therapeutics
CDTX
|
1.38 M | - | - | $ 1.41 B | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Grifols, S.A.
GRFS
|
117 M | $ 8.56 | 2.39 % | $ 6.83 B |